These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T; BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Fazio N; Spada F; Giovannini M Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619 [TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Fazio N; Milione M Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009 [TBL] [Abstract][Full Text] [Related]
5. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. Ali AS; Grönberg M; Federspiel B; Scoazec JY; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET PLoS One; 2017; 12(11):e0187667. PubMed ID: 29112960 [TBL] [Abstract][Full Text] [Related]
6. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study. Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812 [TBL] [Abstract][Full Text] [Related]
7. A pilot study of the immune microenvironment of GI neuroendocrine carcinoma. McDonald A; Avadhani V; Oprea-Ilies G; Zakka K; Lesinski GB; Gbolahan OB; Alese O Endocr Relat Cancer; 2024 Oct; 31(10):. PubMed ID: 39045861 [TBL] [Abstract][Full Text] [Related]
8. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework. de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525 [TBL] [Abstract][Full Text] [Related]
9. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
10. Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma. Sugiyama K; Shiraishi K; Sato M; Nishibori R; Nozawa K; Kitagawa C J Gastrointest Cancer; 2021 Sep; 52(3):947-951. PubMed ID: 32918273 [TBL] [Abstract][Full Text] [Related]
11. Grimaldi F; Fazio N; Attanasio R; Frasoldati A; Papini E; Cremonini N; Davi MV; Funicelli L; Massironi S; Spada F; Toscano V; Versari A; Zini M; Falconi M; Oberg K Endocr Metab Immune Disord Drug Targets; 2018; 18(5):419-449. PubMed ID: 29237387 [TBL] [Abstract][Full Text] [Related]